EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Therapeutic potential and challenges of mesenchymal stem cells in neurological disorders: A concise analysis

Enas H Bani Issa, Enas M Alghazo, Raghad Gharaibeh, Noor B Momani, Dana Z Taha, Renad J Jaradat, Ayman Alzu’bi, Fatimah A Almahasneh, Ejlal Abu-El-Rub, Raed M Al-Zoubi

Journal of Neuropathology & Experimental Neurology · 2025-08-01 · 84 (8) · 668-679

DOI: 10.1093/jnen/nlaf021 ↗
AbstractBibliografische Angaben

Abstract

Abstract Neurological diseases comprise a wide array of conditions affecting both the central and peripheral nervous systems. Neurodegenerative diseases encompass a group of debilitating and often fatal neurological disorders for which effective treatments are currently lacking. Stem cells are recognized for their remarkable capacity for proliferation, multilineage differentiation, and self-renewal. The transplantation of stem cells represents a significant advancement in therapeutic strategies for neurological disorders, with applications in both preclinical and clinical settings. Mesenchymal stem cells (MSCs), in particular, have garnered substantial interest due to their unique properties, making them a highly sought-after source of therapeutic cells. Although the efficacy of MSCs in treating neurological disorders is well documented, further research is needed to elucidate the underlying mechanisms and to assess their in vivo applications more comprehensively. This article summarizes current research on the use of MSCs in the treatment of various neurological disorders, including Parkinson disease, stroke, multiple sclerosis, and Alzheimer disease.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →